Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasm
Conditions
Myeloproliferative Neoplasm
Trial Timeline
Jan 28, 2022 → Apr 9, 2024
NCT ID
NCT05524857About Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg
Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg is a phase 1 stage product being developed by Bristol Myers Squibb for Myeloproliferative Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT05524857. Target conditions include Myeloproliferative Neoplasm.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05524857 | Phase 1 | Terminated |
Competing Products
20 competing products in Myeloproliferative Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 52 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 49 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Ruxolitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 49 |
| Ruxolitinib + Lenalidomide + Prednisone | Incyte | Phase 2 | 49 |
| itacitinib | Incyte | Phase 2 | 49 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 74 |
| INCB160058 + Standard disease-directed therapy | Incyte | Phase 1 | 30 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 49 |
| INCA035784 | Incyte | Phase 1 | 30 |